A functional insertion/deletion polymorphism (-94 ins/del ATTG) in the promoter region of the NFKB1 gene is related to the risk of renal cell carcinoma

Urologia Internationalis

Volumn 91, Issue 2, 2013, Pages 206-212

  Cai, Hongzhou ^a   Sun, Lijiang ^c   Cui, Li ^d   Cao, Qiang ^a   Qin, Chao ^a   Zhang, Guiming ^c   Mao, Xin ^c   Wang, Meilin ^b   Zhang, Zhengdong ^b   Shao, Pengfei ^a   Yin, Changjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^d THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

NFKB1 gene; Polymorphism; Renal cell carcinoma

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR FACTOR KAPPA B 1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHROMOPHOBE CARCINOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIABETES MELLITUS; DRINKING; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERTENSION; INDEL MUTATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING HABIT;

ADULT; AGED; ALCOHOL DRINKING; BODY MASS INDEX; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; INDEL MUTATION; KIDNEY NEOPLASMS; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK; SMOKING;

EID: 84883741767     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345630     Document Type: Article

References (47)

1. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Chow WH, Dong LM, Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-257.
3. Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ: Sex differences in renal cell cancer presentation and survival: An analysis of the National Cancer Database, 1993-2004. J Urol 2008; 179: 1709-1713.
4. Hirata H, Hinoda Y, Nakajima K, et al: The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. J Urol 2009; 18: 721-727.
5. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X: Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010; 31: 1805-1812.
6. Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R: Interleukin-4 promoter polymorphisms: A genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 2007; 25: 845-851.
7. Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007; 52: 1147-1155.
8. Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-928.
9. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
10. Pahl HL: Activators and target genes of Rel/ NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
11. Cao Y, Karin M: NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8: 215-223.
12. Camp ER, Li J, Minnich DJ, et al: Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004; 199: 249-258.
13. Ni J, Takayama K, Inoshima N, et al: Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo. Anticancer Res 2005; 25: 69-77.
14. Salvatore C, Camarda G, Maggi CA, Goso C, Manzini S, Binaschi M: NFkappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. Int J Oncol 2005; 27: 799-806.
15. Dajee M, Lazarov M, Zhang JY, et al: NF-kB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2005; 421: 639-643.
16. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest 2001; 107: 241-246.
17. Oya M, Takayanagi A, Horiguchi A, et al: Increased nuclear factor-kB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003; 24: 377-384.
18. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factorkappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17.
19. Lin L, DeMartino GN, Greene WC: Cotranslational biogenesis of NF-kB p50 by the 26S proteasome. Cell 1998; 92: 819-828.
20. Zhang P, Wei Q, Li X, et al: A functional insertion/ deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet 2009; 191: 73-77.
21. Lo SS, Chen JH, Wu CW, Lui WY: Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery 2009; 145: 280-285.
22. Tang T, Cui S, Deng X, et al: Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol 2009; 28: 1-4.
23. Burnik FS, Yalcin S: NFKB1-94 insertion/ deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009; 55: 381-385.
24. Lehnerdt GF, Bankfalvi A, Grehl S, et al: No association of the NF-kappaB1-94ins/ delATTG promoter polymorphism with relapse-free and overall survival in patients with squamous cell carcinomas of the head and neck region. Int J Immunopathol Pharmacol 2008; 21: 827-832.
25. Riemann K, Becker L, Struwe H, Rubben H, Eisenhardt A, Siffert W: Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007; 45: 423-430.
26. Riemann K, Becker L, Struwe H, et al: No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006; 16: 783-788.
27. Zhou B, Rao L, Li Y, et al: A functional insertion/ deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 2009; 275: 72-76.
28. Lewander A, Butchi AK, Gao J, et al; Swedish Low-Risk Colorectal Cancer Study Group: Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 2007; 42: 1332-1338.
29. Bu H, Rosdahl I, Sun XF, Zhang H: Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007; 133: 859-866.
30. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS: Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2007; 243: 47-54.
31. Zou YF, Yuan FL, Feng XL, et al: Association between NFKB1-94ins/delATTG promoter polymorphism and cancer risk: A meta-analysis. Cancer Invest 2011; 29: 78-85.
32. Qin C, Cao Q, Ju X, et al: The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol 2012; 23: 981-989.
33. Karban AS, Okazaki T, Panhuysen CI, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35-45.
34. Li H, Gao L, Shen Z, et al: Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 2008; 300: 425-433.
35. Sourbier C, Danilin S, Lindner V, et al: Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007; 67: 11668-11676.
36. Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S: NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 2008; 27: 53.
37. Djordjevic G, Matusan-Ilijas K, Sinozic E, et al: Relationship between vascular endothelial growth factor and nuclear factorkappaB in renal cell tumors. Croat Med J 2008; 49: 608-617.
38. Konda R, Sugimura J, Sohma F, et al: Overexpression of hypoxia-inducible protein 2, hypoxia-inducible factor 1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol 2008; 180: 481-485.
39. Kim W, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003; 13: 55-60.
40. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-716.
41. Li X, Liu J, Park JK, et al: T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: A preliminary report. Cancer Res 1994; 54: 5424-5429.
42. Kim HJ, Park JK, Kim YG: Suppression of NF-kappaB activation in normal T cells by supernatant fluid from human renal cell carcinomas. J Korean Med Sci 1999; 14: 299-303.
43. Thornton MV, Kudo D, Rayman P, et al: Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004; 172: 3480-3490.
44. Cao Q, Qin C, Meng X, et al: Genetic polymorphisms in APE1 are associated with renal cell carcinoma risk in a Chinese population. Mol Carcinog 2011; 50: 863-870.
45. Lin J, Pu X, Wang W, et al: Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis 2008; 29: 2112-2119.
46. Terry PD, Umbach DM, Taylor JA: APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking. Int J Cancer 2006; 118: 3170-3173.
47. Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X: Death receptor 4 and bladder cancer risk. Cancer Res 2003; 63: 1157-1159.